December 14, 2017TSI welcomes Annalisa Jenkins, MBBS, FRCP, as a non-executive board member, read the Press Release.
November 15, 2017TSI appoints Michael Woehler, PhD, Chairman of the board, read the Press Release.
September 18, 2017
TSI's first-in-man, randomized, double-blind, placebo-controlled Phase 1 clinical trial demonstrates safety and tolerability of TS01, a sequence of low doses of tPA and HisproUK. Read the Press Release.
December 1, 2016See how the efficacy & safety of therapeutic fibrinolysis can be improved. Read more in the premier cardiology journal JACC.
November 18, 2015TSI, LLC nominated as a Top Biopharma Project to Watch in Cardiovascular by Elsevier Business Intelligence’s Therapeutic Area Partnership Conference organizers. Read more: TSI LLC nominated as a Top Biopharma Project to Watch
June 2, 2015TSI, LLC announces a collaboration with National Institute of Neurological Disorders and Stroke (NINDS) to test a novel thrombolytic regimen for the treatment of Acute Ischemic Stroke in a Phase IIa clinical trial. Read more: TSI, LLC to Collaborate With National Institutes of Health
April 1, 2015A scientific paper by V. Gurewich, MD, TSI’s CSO, is published in the journal PloS One. The paper describes TSI's new drug candidate, a synergistic sequence of low doses of tPA and mutant prourokinase, a more efficient, safer fibrinolytic regimen than can be achieved with traditional monotherapy. Read more.
February 4, 2015The International Stroke Conference is the world’s largest meeting dedicated to the science and treatment of cerebrovascular disease. We will be there. Read more.
October 7, 2014TSI Selected to Present at Cavendish Global Health Impact Forum. Cavendish Global uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences, "TSI to present at the Cavendish Global Health Impact Forum, November 10-13, 2014"
February 19, 2013Cardio. Eng. & Tech. – Scientific paper published comparing TSI’s stroke therapeutic to other thrombolytics and their mechanisms of action, “Fibrinolytic Mechanisms of tPA, prouPA, Mutant prouPA and Their Implications for Therapeutic Thrombolysis“